134 related articles for article (PubMed ID: 38908164)
1. Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights.
De Bruycker A; Schneiders F; Gulstene S; Moghanaki D; Louie A; Palma D; Senan S
Lung Cancer; 2024 Jun; 193():107848. PubMed ID: 38908164
[TBL] [Abstract][Full Text] [Related]
2. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
[TBL] [Abstract][Full Text] [Related]
3. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC).
Lee K; Le T; Hau E; Hanna GG; Gee H; Vinod S; Dammak S; Palma D; Ong A; Yeghiaian-Alvandi R; Buck J; Lim R
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):40-59. PubMed ID: 34879247
[TBL] [Abstract][Full Text] [Related]
7. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
8. Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT.
Sodji QH; Harris JP; Quon A; Modlin LA; Lau B; Jiang A; Trakul N; Maxim PG; Diehn M; Loo BW; Hiniker SM
Clin Lung Cancer; 2022 May; 23(3):282-289. PubMed ID: 35246393
[TBL] [Abstract][Full Text] [Related]
9. What is the predictive value of RECIST criteria following stereotactic lung radiation?
Gulstene S; Lang P; Melody Qu X; Laba JM; Yaremko BP; Rodrigues GB; Yu E; Qiabi M; Nayak R; Malthaner RA; Fortin D; Warner A; Inculet RI; Palma DA
Radiother Oncol; 2024 Jan; 190():109976. PubMed ID: 37918636
[TBL] [Abstract][Full Text] [Related]
10. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
11. New techniques for assessing response after hypofractionated radiotherapy for lung cancer.
Mattonen SA; Huang K; Ward AD; Senan S; Palma DA
J Thorac Dis; 2014 Apr; 6(4):375-86. PubMed ID: 24688782
[TBL] [Abstract][Full Text] [Related]
12. Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics.
Dammak S; Gulstene S; Palma DA; Mattonen SA; Senan S; Ward AD
Sci Rep; 2024 Feb; 14(1):3758. PubMed ID: 38355768
[TBL] [Abstract][Full Text] [Related]
13. Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases.
Siva S; Callahan JW; Kron T; Chesson B; Barnett SA; Macmanus MP; Hicks RJ; Ball DL
Acta Oncol; 2015; 54(8):1105-12. PubMed ID: 25833329
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer.
Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
Med Phys; 2014 Mar; 41(3):033502. PubMed ID: 24593744
[TBL] [Abstract][Full Text] [Related]
15. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
[TBL] [Abstract][Full Text] [Related]
17. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.
Dosani M; Yang R; McLay M; Wilson D; Liu M; Yong-Hing CJ; Hamm J; Lund CR; Olson R; Schellenberg D
Curr Oncol; 2019 Feb; 26(1):e57-e63. PubMed ID: 30853810
[TBL] [Abstract][Full Text] [Related]
18. CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy.
Sawyer B; Pun E; Samuel M; Tay H; Kron T; Bressel M; Ball D; Siva S
J Med Imaging Radiat Oncol; 2015 Apr; 59(2):207-15. PubMed ID: 25601133
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
20. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
